Myriad Genetics Statistics
Total Valuation
Myriad Genetics has a market cap or net worth of $542.92 million. The enterprise value is $645.22 million.
| Market Cap | 542.92M |
| Enterprise Value | 645.22M |
Important Dates
The last earnings date was Wednesday, November 4, 2026, after market close.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Myriad Genetics has 95.92 million shares outstanding. The number of shares has increased by 2.66% in one year.
| Current Share Class | 95.92M |
| Shares Outstanding | 95.92M |
| Shares Change (YoY) | +2.66% |
| Shares Change (QoQ) | +0.95% |
| Owned by Insiders (%) | 4.16% |
| Owned by Institutions (%) | 81.23% |
| Float | 79.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.68 |
| Forward PS | 0.73 |
| PB Ratio | 2.01 |
| P/TBV Ratio | 6.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.98, with a Debt / Equity ratio of 0.78.
| Current Ratio | 1.98 |
| Quick Ratio | 1.55 |
| Debt / Equity | 0.78 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.41 |
Financial Efficiency
Return on equity (ROE) is -40.23% and return on invested capital (ROIC) is -27.80%.
| Return on Equity (ROE) | -40.23% |
| Return on Assets (ROA) | -10.01% |
| Return on Invested Capital (ROIC) | -27.80% |
| Return on Capital Employed (ROCE) | -22.71% |
| Weighted Average Cost of Capital (WACC) | 11.20% |
| Revenue Per Employee | $297,630 |
| Profits Per Employee | -$47,815 |
| Employee Count | 2,700 |
| Asset Turnover | 1.20 |
| Inventory Turnover | 8.46 |
Taxes
| Income Tax | -100,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.46% in the last 52 weeks. The beta is 1.61, so Myriad Genetics's price volatility has been higher than the market average.
| Beta (5Y) | 1.61 |
| 52-Week Price Change | -13.46% |
| 50-Day Moving Average | 4.75 |
| 200-Day Moving Average | 4.61 |
| Relative Strength Index (RSI) | 53.95 |
| Average Volume (20 Days) | 3,246,932 |
Short Selling Information
The latest short interest is 9.27 million, so 9.66% of the outstanding shares have been sold short.
| Short Interest | 9.27M |
| Short Previous Month | 8.55M |
| Short % of Shares Out | 9.66% |
| Short % of Float | 11.65% |
| Short Ratio (days to cover) | 4.59 |
Income Statement
In the last 12 months, Myriad Genetics had revenue of $803.60 million and -$129.10 million in losses. Loss per share was -$1.37.
| Revenue | 803.60M |
| Gross Profit | 549.10M |
| Operating Income | -107.10M |
| Pretax Income | -129.20M |
| Net Income | -129.10M |
| EBITDA | -56.90M |
| EBIT | -107.10M |
| Loss Per Share | -$1.37 |
Balance Sheet
The company has $107.10 million in cash and $209.40 million in debt, with a net cash position of -$102.30 million or -$1.07 per share.
| Cash & Cash Equivalents | 107.10M |
| Total Debt | 209.40M |
| Net Cash | -102.30M |
| Net Cash Per Share | -$1.07 |
| Equity (Book Value) | 269.00M |
| Book Value Per Share | 2.81 |
| Working Capital | 134.30M |
Cash Flow
In the last 12 months, operating cash flow was -$19.90 million and capital expenditures -$14.00 million, giving a free cash flow of -$33.90 million.
| Operating Cash Flow | -19.90M |
| Capital Expenditures | -14.00M |
| Depreciation & Amortization | 50.20M |
| Net Borrowing | -100,000 |
| Free Cash Flow | -33.90M |
| FCF Per Share | -$0.35 |
Margins
Gross margin is 68.33%, with operating and profit margins of -13.33% and -16.07%.
| Gross Margin | 68.33% |
| Operating Margin | -13.33% |
| Pretax Margin | -16.08% |
| Profit Margin | -16.07% |
| EBITDA Margin | -7.08% |
| EBIT Margin | -13.33% |
| FCF Margin | n/a |
Dividends & Yields
Myriad Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.66% |
| Shareholder Yield | -2.66% |
| Earnings Yield | -24.16% |
| FCF Yield | -6.24% |
Analyst Forecast
The average price target for Myriad Genetics is $5.44, which is -3.92% lower than the current price. The consensus rating is "Hold".
| Price Target | $5.44 |
| Price Target Difference | -3.92% |
| Analyst Consensus | Hold |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | -1.54% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on March 26, 2009. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 26, 2009 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Myriad Genetics has an Altman Z-Score of -0.98 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.98 |
| Piotroski F-Score | 2 |